Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
A 2:1:1 mixture of: trisodium N(1')-N(2):N(1''')-N(2'')-η-6-[2-amino-4-(or 6)-hydroxy-(or 4-amino-2-hydroxy)phenylazo]-6''-(1-carbaniloyl-2-hydroxyprop-1-enylazo)-5',5'''-disulfamoyl-3,3''-disulfonatobis(naphthalene-2,1'-azobenzene-1,2'-diolato-O(1),O(2'))-chromate; trisodium N(1')-N(2):N(1''')-N(2'')-η-6,6''-bis(1-carbaniloyl-2-hydroxyprop-1-enylazo)-5',5'''-disulfamoyl-3,3''-disulfonatobis(naphthalene-2,1'azobenzene-1,2'-diolato-O(1),O(2'))-chromate; trisodium N(1')-N(2):N(1''')-N(2'')-η-6,6''-bis[2-amino-4-(or 6)-hydroxy-(or 4-amino-2-hydroxy)phenylazo]5',5'''-disulfamoyl-3,3''-disulfonatobis(naphthalene-2,1'azobenzene-1,2'-diolato-O(1),O(2'))-chromate
EC number: 402-850-1 | CAS number: - NOIR SANDODERM HH 1050; SANDODERM BLACK HH 1050; SANDODERM BLACK R; SANDODERM BLACK R CONC.; SANDODERM SCHWARZ R; SANDODERM SCHWARZ R KONZ.
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro gene mutation study in bacteria
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- From 25. Nov. to 14. Dec. 1987
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
- Remarks:
- Only four strains were used in accordance with the replaced OECD guideline (1983)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 987
- Report date:
- 1987
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Version / remarks:
- 1983
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.13/14 (Mutagenicity - Reverse Mutation Test Using Bacteria)
- Version / remarks:
- 1984
- Deviations:
- no
- GLP compliance:
- yes
- Type of assay:
- bacterial reverse mutation assay
Test material
- Reference substance name:
- A 2:1:1 mixture of: trisodium N(1')-N(2):N(1''')-N(2'')-η-6-[2-amino-4-(or 6)-hydroxy-(or 4-amino-2-hydroxy)phenylazo]-6''-(1-carbaniloyl-2-hydroxyprop-1-enylazo)-5',5'''-disulfamoyl-3,3''-disulfonatobis(naphthalene-2,1'-azobenzene-1,2'-diolato-O(1),O(2'))-chromate; trisodium N(1')-N(2):N(1''')-N(2'')-η-6,6''-bis(1-carbaniloyl-2-hydroxyprop-1-enylazo)-5',5'''-disulfamoyl-3,3''-disulfonatobis(naphthalene-2,1'azobenzene-1,2'-diolato-O(1),O(2'))-chromate; trisodium N(1')-N(2):N(1''')-N(2'')-η-6,6''-bis[2-amino-4-(or 6)-hydroxy-(or 4-amino-2-hydroxy)phenylazo]5',5'''-disulfamoyl-3,3''-disulfonatobis(naphthalene-2,1'azobenzene-1,2'-diolato-O(1),O(2'))-chromate
- EC Number:
- 402-850-1
- EC Name:
- A 2:1:1 mixture of: trisodium N(1')-N(2):N(1''')-N(2'')-η-6-[2-amino-4-(or 6)-hydroxy-(or 4-amino-2-hydroxy)phenylazo]-6''-(1-carbaniloyl-2-hydroxyprop-1-enylazo)-5',5'''-disulfamoyl-3,3''-disulfonatobis(naphthalene-2,1'-azobenzene-1,2'-diolato-O(1),O(2'))-chromate; trisodium N(1')-N(2):N(1''')-N(2'')-η-6,6''-bis(1-carbaniloyl-2-hydroxyprop-1-enylazo)-5',5'''-disulfamoyl-3,3''-disulfonatobis(naphthalene-2,1'azobenzene-1,2'-diolato-O(1),O(2'))-chromate; trisodium N(1')-N(2):N(1''')-N(2'')-η-6,6''-bis[2-amino-4-(or 6)-hydroxy-(or 4-amino-2-hydroxy)phenylazo]5',5'''-disulfamoyl-3,3''-disulfonatobis(naphthalene-2,1'azobenzene-1,2'-diolato-O(1),O(2'))-chromate
- Molecular formula:
- not applicable for UVCB substance
- IUPAC Name:
- trichromium(3+) nonasodium 6-[2-(2-amino-4-hydroxyphenyl)diazen-1-yl]-2-[2-(2-oxido-5-sulfamoylphenyl)diazen-1-yl]-3-sulfonatonaphthalen-1-olate 6-[2-(2-amino-6-hydroxyphenyl)diazen-1-yl]-2-[2-(2-oxido-5-sulfamoylphenyl)diazen-1-yl]-3-sulfonatonaphthalen-1-olate 6-[2-(4-amino-2-hydroxyphenyl)diazen-1-yl]-2-[2-(2-oxido-5-sulfamoylphenyl)diazen-1-yl]-3-sulfonatonaphthalen-1-olate tris(6-{2-[(1Z)-2-hydroxy-1-(phenylcarbamoyl)prop-1-en-1-yl]diazen-1-yl}-2-[2-(2-oxido-5-sulfamoylphenyl)diazen-1-yl]-3-sulfonatonaphthalen-1-olate)
- Test material form:
- solid: particulate/powder
Constituent 1
Method
- Target gene:
- Salmonella typhimurium strain LT2 TA 1535, TA 1537, TA 98, TA 100
Species / strain
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Details on mammalian cell type (if applicable):
- CELLS USED
- Source of cells: SIGMA, 8024 Deisenhofen, DE and SERVA, 6900 Heidelberg, DE
- Suitability of cells: strains of S. typhimurium strain LT2 are histidine-dependent due to a mutation in the histidine locus; the cells are easily penetrable due to rfa-minus mutation causing a faulty lipopolysaccharide envelope; it has a reduced inherent excision repair system due to another mutation; TA 98 and TA100 strains contain the ampicillin resistance marker in the R-factor plasmid pKM 101
- Storage: as stock cultures in ampoules with nutrient broth and 5 % DMSO in liquid nitrogen
- Precultures: 0.5 ml bacterial suspension was thawed and transferred to 250 ml erlenmeyer flasks containing 20 ml nutrient medium (Difco Nutient Broth, 8 g/l; NaCl, 5 g/l), then incubated in a shaking water bath for 6 hours at 37 °C
MEDIA USED
- Selective agar: 20 ml of 1.5 % Vogel-Bonner-Glucose-Minimal-Agar
- Overlay agar: Difco Bacto Agar (6 g/l), NaCl (6 g/l), L-histidine x HCl x H20 (10.48 mg/l) and biotin (12.20 mg/l)
- Sterilisation: 121 °C in an autoclave
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9 liver microsomal fraction, obtained from the liver of 8 to 12 week old male Wistar rats, protein concentration 20 to 45 mg/ml, and mixed with S9 cofactor solution in a ratio of 3:7
- Test concentrations with justification for top dose:
- Pre-test concentrations: 1, 3, 10, 33, 100, 333, 1000, 5000 µg/plate
Toxicity was observed (reduced count of revertants per plate) at concentration of 5000 µ/plate, both with and without S9 mix, in both TA 98 and TA 100 strains.
Based on the pre-test results, the following experimental concentrations were selected: 10, 100, 333.3, 1000 and 5000 µg/plate - Vehicle / solvent:
- DMSO
Controlsopen allclose all
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Positive controls:
- yes
- Positive control substance:
- sodium azide
- other: 4-nitro-o-phenylene-diamine;
- Remarks:
- without metabolic activation
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Positive controls:
- yes
- Positive control substance:
- other: 2-aminoanthracene
- Remarks:
- with metabolic activiation
- Details on test system and experimental conditions:
- PRE-TEST FOR TOXICITY:
In order to select suitable concentrations of test item for the experimental study which produced some toxicity at the highest dose, the count of revertants per plate at 1, 3, 10, 33, 100, 333, 1000 and 5000 µg/plate of test item was compared to count of revertants of a negative control, solvent control and three positive controls (4-NOPD, 50 µg; sodium azide, 10 µg; 2-aminoantracene, 10 µg). Toxicity by reduced count of revertants was observed at the highest dose, 5000 µg/plate. Therefore, the experimental concentrations selected were 10, 100, 333.3, 1000 and 5000 µg/plate.
PREPARATIONS:
- Bacterial suspensions: ampoules of the four strains were thawed and 0.5 ml bacterial suspensions were transferred to 250 ml erlenmeyer flasks containing 20 ml nutrient medium (8 g/l Difco Nutrient Broth and 5 g/l NaCl). The bacterial culture was incubated in a shaking water bath for 6 hours at 37 °C.
- Agar plates: each petri dish was filled with 20 ml of agar medium (1.5 % Vogel-Bonner-Glucose-Minimal-Agar)
- Overlay agar: 6 g/l Difco Bacto Agar, 6 g/l NaCl, 10.48 mg/l L-histidine x HCl x H2O, 12.2 mg/l biotin
- S9: S9 liver microsomal fraction was obtained from the liver of 8 to 12 week old male Wistar rats which received a single i.p. injection of 500 mg/kg bw Aroclor 1254 in olive oil 5 days previously. After cervical dislocation, the livers of the animals were removed, washed in 150 mM KCl and homogenised. The homogenate was diluted 1:3 in KCl and centrifuged cold at 9000 g for 10 minutes. A stock of the supernatant containing the microsomes was frozen in ampoules of 2 or 5 ml and stored at -70 °C. Small numbers of the ampoules were kept at -20 °C for only several weeks before use. The standardisation of the protein content was made using the analysis kit of Bio-Rad Laboratories. The protein concentration in the S9 preparation was 20 to 45 mg/ml.
- S9 mix: S9 was mixed with S9 cofactor solution in a ratio 3:7 to yield the following concentrations: 8 mM MgCl2; 33 mM KCl; 5 mM glucose-6-phosphate; 5 mM NADP; 100 mM sodium-ortho-phosphate-buffer, pH 7.4.
METHOD:
i) Each test strain was tested both with and without metabolic activation, at all 5 test item concentrations, with an appropriate positive control, and with both a negative control and a solvent, in triplicate. The following materials were mixed in a test tube and poured onto the pre-prepared minimal agar plates:
- 100 µl test item at selected dose level (10, 100, 333, 1000 or 5000 µl), solvent (negative control), or reference mutagen solution (positive control)
- 500 µl S9 mix ("with metabolic activtion") or S9 mix substitution buffer ("without metabolic activation")
- 100 µl bacterial suspension (TA 1535, TA 1537, TA 98 or TA 100)
- 2000 µl overlay agar, pre-prepared
ii) Plates were allowed to solidify, then were incubated upside down for 72 hours at 37 °C in the dark.
iii) Colonies were counted using the BIOTRAN III counter (BIOTRONIK, 6000 Frankfurt, DE). - Rationale for test conditions:
- The most widely used assays for detecting gene mutations are those using bacteria. They are relatively simple and rapid to perform, and give reliable data on the ability of an agent to interact with DNA and produce mutations. However, the bacteria most commonly used in these assays do not possess enzyme systems which, in mammals, convert promutagens into active DNA damaging metabolites. In order to overcome this major drawback, an exogenous metabolic system is added in form of mammalian microsome enzyme activation mixture.
In spite of great differences between bacterial and eukaryotic cells with respect to structure and function, there is an association between mutagenicity in bacteria and carcinogenicity in mammals. Reverse mutation assays determine the frequency at which an agent abolishes or suppresses the effect of the forward mutation. The genetic target presented to an agent is therefore small, specific and selective. Several bacterial strains, or a single strain with multiple markers are necessary to overcome the effects of mutagen specificity. The reversions of bacteria from growth-dependence on a particular amino acid to growth in the absence of that amino acid (reversion from auxothrophy to prototrophy) is the most widely used marker.
The Salmonella typhimurium histidine (his) reversion system measures his- to his+ reversions. The S. typhimurium strains are constructed to differentiate between base pair (TA 1535, TA 100) and frameshift (TA 1537, TA 98) mutations. According to the direct plate incorporation method, the bacteria are exposed to the test article with and without metabolic activation and plated on selective medium. After a suitable incubation period, revertant colonies are counted.
To establish a dose response effect, at least 5 dose levels with adequately spaced intervals are tested. The maximum dose level is 5000 µg/plate unless limited by toxicity or solubility of the test item. To validate the test, parallel reference mutagens are tested. - Evaluation criteria:
- A test item is considered as positive to mutagenicity if either a significant dose-related increase in the number of revertants or a significant and reproducible increase for at least one test concentration is induced. A test item producing neither a significant dose-related increase in the number of revertants nor a significant and reproducible positive response at any one of the test points is considered non-mutagenic in this system.
A significant response is described as follows:
A test item is considered a mutagen if in strain TA 100 the number of reversions is at least twice as high and in strains TA 1535, TA 1537 and TA 98 it is at least three times higher as compared to the spontaneous reversion rate. A dose-dependent increase in the number of revertants is regarded as an indication ofpossibly existing mutagenic potential of the test article regardless of whether the highest dose induced the described enhancement factors or not.
RANGE OF SPONTANEOUS REVERSION FREQUENCIES
The generally accepted conditions for the evaluation of the results are:
- corresponding background growth on both negative control and test plates; and
- normal range of spontaneous reversion rates.
TA 1535: 3 to 37
TA 1537: 4 to 31
TA 98: 15 to 60
TA 100: 75 to 200 - Statistics:
- A statistical evaluation of the results is recommended according to international guidelines, however, no evaluated statistical procedure can be recommended for analysis of data from the bacterial assays at this time.
Results and discussion
Test results
- Species / strain:
- other: S. typhimurium TA 1535, TA 1537, TA 98, TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- PRELIMINARY EXPERIMENT FOR TOXICITY
- 8 concentrations were tested for toxicity and mutation induction with each 3 plates.
- According to the dose selection criteria, the test article was tested at the following concentrations: 10, 100, 333.3, 1000, and 5000 µg/plate.
MAIN STUDY
- Toxic effects, evidenced by a reduction in the number of spontaneous revertants, occurred in some test groups with and without metabolic activation at the highest investigated dose. The plates incubated with the test article showed normal background growth of up to 5000 µg/plate with and without S9 mix in all strains used.
- Up to the highest investigated dose, no significant dose-depandant increase in revertant colony numbers was obtained in all Salmonella typhimurium strains used. The presence of liver microsomal activation did not influance thesa findings.
- Appropriate reference mutagens were used as positive controls and showed a distinct increase of induced revertant colonies. During the described mutagenicity test and under the experimental conditions reported, the test article did not induce point mutations by base pair changes or frameshifts in the genome of the strains used.
Applicant's summary and conclusion
- Conclusions:
- The test item was found not to be mutagenic in Salmonella typhimurium in the absence or presence of metabolic activation, under the reported experimental conditions.
- Executive summary:
This study was performed to investigate the potential of the test item to induce gene mutations according to the plate incorporation test using the Salmonella typhimurium strains TA 1535, TA 1537, TA 98 and TA 100 according to the OECD Guideline 471 (1983) and the EU Method B.14 (1984). The assay was performed in two independent experiments, using identical procedures, both with and without liver microsomal activation. Each concentration, including the controls, was tested in triplicate. The test article was tested at the following concentrations: 10.0; 100.0; 333.3; 1000.0; and 5000.0 µg/plate.
Toxic effects, evidenced by a reduction in the number of spontaneous revertants, occurred in some test groups with and without metabolic activation at the highest investigated dose. The plates incubated with the test item showed normal background growth up to 5000.0 µg/plate with and without S9 mix in all strains used.
Up to the highest investigated dose, no significant dose dependant increase in revertant colony numbers was obtained in all Salmonella typhimurium strains used. The presence of liver microsomal activation did not influence these findings.
Appropriate reference mutagens were used as positive controls and showed a distinct increase of induced revertant colonies.
In conclusion, it can be stated that during the described mutagenicity test and under the experimental conditions reported, the test item did not induce point mutations by base pair changes or frameshifts in the genome of the strains used. Therefore, the substance is not considered to be mutagenic in this Salmonella typhimurium reverse mutation assay.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.